Phase 2 N=17 LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgkin's Lymphoma
Primary: Complete Remission — 10 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=67 Diffuse Large B Cell Non-Hodgkin's Lymphoma in the Vulnerable/Frail Elderly. A Multicentric Randomized Phase II Trial
Lymphoma
Primary: Number of Participants in Complete Remission 6 Months After Randomization — 14; 9 Participants
Phase 2 N=57 A Study for Patients With Non-Hodgkin's Lymphomas
T-Cell Lymphoma · B-Cell Lymphoma
Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…
Phase 3 N=322 Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Primary: Event-free Survival (EFS) Per Blinded Independent Review Committee (BIRC) Assessment — 3.0; 3.0 months — p== 0.694
Phase 2 N=31 Antineoplaston Therapy in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Low-Grade Lymphoma
Primary: Number of Participants With Objective Response — 1; 2; 14; 6 Participants
Phase 2 N=86 S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival (PFS) at 2 Years — 69 percentage of participants
Phase 3 N=253 SWOG-9704 Chemoradiotherapy and Peripheral Stem Cell Transplantation Compared With Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Overall Survival Rates — 71.1; 73.7 percentage of participants
Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Phase 2 N=34 Brentuximab Vedotin Plus AD in Non-bulky Limited Stage Hodgkin Lymphoma
Hodgkin Lymphoma
Primary: Complete Response Rate — 34 Participants
Phase 2 N=14 Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
Anaplastic Large Cell Lymphoma · Angioimmunoblastic T-cell Lymphoma · Hepatosplenic T-cell Lymphoma
Primary: Overall Response (OR) Rate — 0.07 Proportion of participants
Phase 2 N=106 Combination Chemotherapy and Rituximab in Treating Patients With HIV-Associated Stage I, Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Immunoblastic Large Cell Lymphoma · AIDS-related Peripheral/Systemic Lymphoma
Primary: Complete Response Proportion as Measured by Tumor Response After Completion of Study Treatment — 0.69; 0.53 proportion
Phase 2 N=39 Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Lymphoma, B-Cell
Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants
Phase 2 N=100 Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: 2-year Progression-Free Survival (PFS) — 0.76; 0.42 probability
Phase 2 N=46 S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Phase 3 N=524 Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Large B Cell Lymphoma
Primary: Progression-Free Survival Rate at 2 and 5 Years — 78.9; 75.5; 68.0; 66.0 percentage of participants — p=0.6519
Phase 2 N=47 Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma
High-risk Diffuse Large B-Cell Lymphoma
Primary: Participants With Treatment-Emergent (Blinatumomab) Adverse Events — 28; 11; 5; 7 Participants
Phase 2 N=473 Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma
Lymphoma
Primary: Number of Participants With 1 Year Progression Free Survival — 112; 102; 1; 2 Participants
Phase 3 N=571 S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma
Lymphoma
Primary: Progression-free Survival at 2 Years — 76; 80 percentage of participants — p=0.11
Phase 2 N=87 S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Lymphoma
Primary: Percentage of Participants With 3-year Progression-free Survival (PFS) — 90 percentage of participants
Phase 2 N=7 Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
AIDS-related Diffuse Large Cell Lymphoma · AIDS-related Diffuse Mixed Cell Lymphoma · AIDS-related Diffuse Small Cleaved Cell Lymphoma
Primary: Overall Survival — 0; 0 Proportion of participants
Phase 2 N=96 Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
Phase 2 N=77 Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
Lymphoma, Non-Hodgkin
Primary: Number of Participants With Confirmed Response, Including Participants With Complete Response (CR), Clinical Complete Response (CCR), and Partial Response (PR) — 72…
Phase 2 N=38 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
Adult Non-Hodgkin Lymphoma · Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Nodal Marginal Zone Lymphoma
Primary: Maximum Tolerated Dose of CpG 7909 as Determined Using the Number of Participants With a DLT at Each Dose Level — 0; 1; 0; 1 participants
Phase 2 N=67 Multicenter Trial to Treat Patients With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma
Leukemia · Lymphoma
Primary: Objective Response Rate — 2; 4; 6; 17 Participants
Phase 2 N=23 PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma
B-Cell Lymphoma
Primary: Clinical Response Rate — 1; 7; 0; 8 Participants
Phase 2 N=60 Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
Lymphoma
Primary: Progression — 22; 1 participants — p=0.51
Phase 2 N=17 Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma
Leukemia · Lymphoma
Primary: Survival at 1 Year After Transplantation — 10; 6 participants
Phase 2 N=48 Study of Alisertib (MLN8237) in Adults With Aggressive Non-Hodgkin's Lymphoma
Diffuse Large B-cell Lymphoma · Mantle Cell Lymphoma · Burkitt's Lymphoma
Primary: Best Overall Response Rate Based on Investigator's Assessment (Applying the IWG 2007 Response Criteria) — 25; 23; 40; 100 percentage of participants
Phase 2 N=24 Rituximab and Denileukin Diftitox in Treating Patients With Previously Untreated Stage III or Stage IV Follicular B-Cell Non-Hodgkin's Lymphoma
Lymphoma
Primary: Proportion of Confirmed Tumor Response (Complete Response [CR], Unconfirmed CR, and Partial Response) — 0.48 proportion of participants
Phase 1 N=133 Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma
Hodgkin Lymphoma · Non-Hodgkin Lymphoma
Primary: Number of Participants Who Experienced Dose-Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants